RESULTS	Continuing natalizumab in the second trial resulted in higher rates of sustained response ( 61 percent vs. 28 percent , P < 0.001 ) and remission ( 44 percent vs. 26 percent , P = 0.003 ) through week 36 than did switching to placebo .\